Rezolute Shares Plunge 90% After Phase 3 Trial Failure of ersodetug
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Stock Crash: On December 11, 2025, Rezolute, Inc. announced that its Phase 3 trial for ersodetug failed to meet its primary endpoint, causing shares to plummet by as much as 90% intraday, significantly undermining investor confidence and triggering market panic.
- Investor Disappointment: The company had assured investors in mid-November that ersodetug would substantially improve the quality of life for individuals with hyperinsulinism, but the trial results contradicted these claims, leading to severe doubts about the company's future commercial prospects.
- Analyst Reaction: Following the trial results, analysts quickly downgraded Rezolute's rating from outperform to neutral and slashed the price target from $12 to $1, reflecting a pessimistic outlook on the company's future.
- Legal Investigation Initiated: In response to the severe market reaction, Hagens Berman law firm has launched an investigation into whether Rezolute misled investors regarding ersodetug's efficacy and commercial potential, which could lead to further legal ramifications.
RZLT
$2.24+Infinity%1D
Analyst Views on RZLT
Wall Street analysts forecast RZLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RZLT is 16.14 USD with a low forecast of 12.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.430
Low
12.00
Averages
16.14
High
20.00
Current: 2.430
Low
12.00
Averages
16.14
High
20.00
About RZLT
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
